THE 60-SECOND GUIDE
Wolverine Stack
Unsupported combination.
Guide prepared November 13, 2026 · profile review dates retained

What is it?
Wolverine is an informal name usually used for BPC-157 plus TB-500. It is not a standardized medicine, and component research does not establish that the combination improves healing in people. [1]
Potential benefits
BPC-157 and TB-500 are separately discussed in laboratory and preclinical research. The popularity of pairing them does not establish that the combination improves healing or recovery in people. No controlled human evidence is cited here for a standardized product called Wolverine Stack. [1]
Evidence & its limits
No controlled human combination study is cited here. The nickname does not guarantee a consistent formulation, and research on full-length thymosin beta-4 cannot automatically be assigned to a TB-500 fragment or mixture. [1]
Risks & unknowns
The combination has no FDA-approved product or indication. FDA identifies limited safety information and peptide-quality or immunogenicity concerns for BPC-157 and the thymosin beta-4 fragment known as TB-500. Combined safety, interactions, product identity, sterility, and long-term outcomes are not established. [1]
Status & scope
The combination has no FDA-approved product or indication. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA · safety risks for nominated compounding substances
- FDA · May 11, 2026 BPC-157 evaluation
- PubMed · 2025 orthopaedic peptide review
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.